[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342165-105":59,"doc-detail-342165-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","botensilimab-an-fc-enhanced-anti-ctla-4-antibody-is-effective-against-tumors-poorly-responsive-to-conventional-immunotherapy","Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy","","Botensilimab, an Fc-enhanced anti–CTLA-4 antibody, is evaluated for activity in cancers that poorly respond to conventional immune checkpoint inhibitors. The study shows that enhancing FcγR affinity enables FcγR-dependent mechanisms that increase T-cell responsiveness, reduce intratumoral regulatory T cells, and activate antigen-presenting cells. In mouse models, Fc-enhanced anti–CTLA-4 produces superior tumor efficacy and reshapes innate and adaptive immunity. Clinical activity in multiple difficult-to-treat, ICI-refractory tumors occurs independently of tumor neoantigen burden or FCGR3A genotype, with FCGR2A and FCGR3A expression emerging as potential biomarkers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/botensilimab-an-fc-enhanced-anti-ctla-4-antibody-is-effective-against-tumors-poorly-responsive-to-conventional-immunotherapy/342165/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/botensilimab-an-fc-enhanced-anti-ctla-4-antibody-is-effective-against-tumors-poorly-responsive-to-conventional-immunotherapy/342165.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main mechanism proposed for Fc-enhanced anti–CTLA-4 activity in this study?","Question",{"text":112,"@type":113},"Fc-enhanced anti–CTLA-4 leverages FcγR-dependent mechanisms to potentiate T-cell responsiveness, reduce intratumoral regulatory T cells, and enhance antigen-presenting cell activation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Does botensilimab efficacy depend on tumor neoantigen burden or FCGR3A genotype?",{"text":117,"@type":113},"Clinical activity is described as independent of tumor neoantigen burden and FCGR3A genotype across multiple poorly immunogenic, ICI treatment–refractory cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"Which biomarkers are suggested for response?",{"text":121,"@type":113},"FCGR2A and FCGR3A expression are highlighted as potential response biomarkers, despite lack of dependence on FCGR3A genotype alone.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342165,1790207999,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","ReseaRch aRticle  \nBotensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy   \nDhan Chand1, David A. Savitsky1, Shanmugarajan Krishnan1, Gabriel Mednick1, Chloe Delepine1,  \nPilar Garcia-Broncano1, Kah Teong Soh1, Wei Wu1, Margaret K. Wilkens1, Olga Udartseva1, Sylvia Vincent1, Bishnu Joshi1, Justin G. Keith1, Mariana Manrique1, Marilyn Marques1, Antoine Tanne1, Daniel L. Levey1, Haiyong Han2, Serina Ng2, Jackson Ridpath1, Olivia Huber1, Benjamin Morin1, Claire Galand1,  \nSean Bourdelais1, Randi B. Gombos1, Rebecca Ward1, Yu Qin1, Jeremy D. Waight1, Matthew R. Costa1, Alvaro Sebastian-Yague1, Nils-Petter Rudqvist1, Malgorzata Pupecka-Swider1, Vignesh Venkatraman1, Andrew Slee1, Jaymin M. Patel1, Joseph E. Grossman1, Nicholas S. Wilson1, Daniel D. Von Hoff2,  \nJustin Stebbing3, Tyler J. Curiel1,4, Jennifer S. Buell1,5, Steven J. O’Day1, and Robert B. Stein1,5  \nConventional immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte  \nantigen 4 (CTLA-4) elicit durable survival but primarily in patients with immuneinflamed tumors. Although the mechanisms underlying response to anti–CTLA-4 remain poorly understood, Fc-gamma receptor (FcγR) IIIA coengagement seems critical for activity, potentially explaining the modest clinical benefits of approved anti–CTLA-4 antibodies. We demonstrate that anti–CTLA-4 engineered for enhanced FcγR affinity leverages FcγR-dependent mechanisms to potentiate T-cell responsiveness, reduce intratumoral regulatory T cells, and enhance antigen-presenting cell activation. Fc-enhanced anti–CTLA-4 promoted superior efficacy in mouse models and remodeled innate and adaptive immunity versus conventional anti–CTLA-4 . These findings extend to patients treated with botensilimab, an Fc-enhanced anti–CTLA-4 antibody, with clinical activity across multiple poorly immunogenic and ICI treatment–refractory cancers. Efficacy was independent of tumor neoantigen burden or FCGR3A genotype. However, FCGR2A and FCGR3A expression emerged as potential response biomarkers. These data highlight the therapeutic potential of Fc-enhanced anti–CTLA-4 antibodies in cancers unresponsive to conventional ICI therapy.  \nSIgnIFICAnCE: This study reveals that Fc-enhanced anti–CTLA-4 harnesses novel mechanisms to overcome the limitations of conventional anti–CTLA-4, effectively treating poorly immunogenic and treatment-refractory cancers. Our findings support the development of a new class of immunooncology agents, capable of extending clinical benefit to patients with cancers resistant to current immunotherapies.  \nintRoduction  \nImmune checkpoint inhibitors (ICI) blocking cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and PD-L1 have revolutionized treatments of many cancers. However, responses to approved ICI agents occur ina minority of tumors, and ICI resistance remains a barrier to optimal clinical benefit. CTLA-4 was the first immune checkpoint described (1–3) . It negatively regulates T-cell activation by modulating costimulatory signals within the immunologic synapse between antigen-presenting cells (APC) and T cells. During T-cell priming, CTLA-4 is upregulated on T cells to outcompete binding of costimulatory CD28 to CD80 and CD86, thereby impairing T-cell activation (4, 5). Furthermore, CTLA-4 is highly expressed on regulatory T cells (Treg) and modulates their suppressive functions (6) .  \nIn mouse tumor models, anti–CTLA-4 (αCTLA-4) boosts tumor-reactive T-cell activation and selectively eliminates CTLA-4–expressing intratumoral Tregs (7, 8) that impair  \n1Agenus Inc, Lexington, Massachusetts. 2The Translational Genomics Research Institute, Phoenix, Arizona. 3Anglia Ruskin University, Cambridge, United Kingdom. 4Dartmouth Cancer Center and the Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. 5MiNK Therapeutics, Lexington, Massachusetts.  \nCorresponding Author: Dhan Chand, Agenus Inc, 3 Forbes Road, Lexing","cbCailIlsIhXjPQZ","https://ap.wps.com/l/cbCailIlsIhXjPQZ","pdf",8018849,23,"English","# Introduction\n## Immune checkpoint inhibitors and CTLA-4 biology\n## FcγR dependence and engineered anti–CTLA-4 rationale","[{\"question\":\"What is the main mechanism proposed for Fc-enhanced anti–CTLA-4 activity in this study?\",\"answer\":\"Fc-enhanced anti–CTLA-4 leverages FcγR-dependent mechanisms to potentiate T-cell responsiveness, reduce intratumoral regulatory T cells, and enhance antigen-presenting cell activation.\"},{\"question\":\"Does botensilimab efficacy depend on tumor neoantigen burden or FCGR3A genotype?\",\"answer\":\"Clinical activity is described as independent of tumor neoantigen burden and FCGR3A genotype across multiple poorly immunogenic, ICI treatment–refractory cancers.\"},{\"question\":\"Which biomarkers are suggested for response?\",\"answer\":\"FCGR2A and FCGR3A expression are highlighted as potential response biomarkers, despite lack of dependence on FCGR3A genotype alone.\"}]","Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy | PDF",1790045627,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb896201a6cd7a226c9fad9e0ef13597.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c482cabe9fc005b41bfe2a1efd9c9b0.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29c778926aea922a96ffbf29b3c6147b.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e214ca4fd5b85a5f29dbd5fc7f74d6d7.webp",980,1311]